80

ProstateCancer

• How to reduce the risk of erectile dysfunction following prostate cancer surgery - Examiner.com 17 May, 2012, 11:04 am
  ScienceBlog.comHow to reduce the risk of erectile dysfunction following prostate cancer surgeryExaminer.comAccording to UCLA Health System, excluding skin cancer, prostate cancer is the most commonly diagnosed cancer in the United States. A common surgical procedure for the malignancy is a radical prostatectomy. In addition to erectile dysfunction, ...To remove prostate find experienced surgeonUPI.comWant to Avoid ED Following Prostate Cancer Surgery? Find an Experienced ...Newswise (press release)Need Prostate Surgery? Be Patient No. 1001MyHealthNewsDailyall 12 news articles »
• Protein RAL associated with aggressive characteristics in prostate, bladder ... - Science Codex 17 May, 2012, 10:37 am
  Protein RAL associated with aggressive characteristics in prostate, bladder ...Science CodexFrom metastasis in bladder cancer, to seminal vessel involvement in prostate cancer, to shortened survival in squamous cell carcinoma, a study published this week in the journal Cancer Research shows that proteins RalA and RalB are associated with ...and more »
• ASCO: Abiraterone Tolerated in High-Risk Prostate Cancer - Doctors Lounge 17 May, 2012, 10:10 am
  ASCO: Abiraterone Tolerated in High-Risk Prostate CancerDoctors LoungeFor men with localized high-risk prostate cancer, neoadjuvant androgen deprivation therapy with abiraterone acetate plus leuprolide acetate is well tolerated and has good pathological complete/near complete response rates, according to a study released ...
• Protein RAL associated with aggressive characteristics in prostate, bladder ... - Medical Xpress 17 May, 2012, 10:04 am
  Protein RAL associated with aggressive characteristics in prostate, bladder ...Medical XpressFrom metastasis in bladder cancer, to seminal vessel involvement in prostate cancer, to shortened survival in squamous cell carcinoma, a study published this week in the journal Cancer Research shows that proteins RalA and RalB are associated with ...and more »
• Orange County Register's Gary Lycan Battling Cancer - mediabistro.com 17 May, 2012, 9:56 am
  Orange County Register's Gary Lycan Battling Cancermediabistro.comBy Matthew Fleischer on May 17, 2012 9:52 AM Orange County Register media reporter Gary Lycan went public with his battle with advanced prostate cancer in his most recent column. He gave a nice shout-out to the team treating him at St. Joseph Cancer ...
• Protein RAL associated with aggressive characteristics in prostate, bladder ... - EurekAlert (press release) 17 May, 2012, 9:23 am
  Protein RAL associated with aggressive characteristics in prostate, bladder ...EurekAlert (press release)From metastasis in bladder cancer, to seminal vessel involvement in prostate cancer, to shortened survival in squamous cell carcinoma, a study published this week in the journal Cancer Research shows that proteins RalA and RalB are associated with ...
• Dendreon Declines as J&J Rival to Provenge Shows Benefits - BusinessWeek 17 May, 2012, 8:06 am
  Dendreon Declines as J&J Rival to Provenge Shows BenefitsBusinessWeek(DNDN) (DNDN), maker of the prostate cancer drug Provenge, dropped to its lowest value in four months after Johnson & Johnson (JNJ) (JNJ)'s rival medicine Zytiga helped high-risk patients in a study. Dendreon fell 9.5 percent to $7.80 at 9:39 am after ...Dendreon Announces Presentation of PROVENGE Data at the 2012 American Society ...MarketWatch (press release)Dendreon: SEC Opens Probe, Possibly Tied To Provenge DisclosuresWall Street JournalDendreon's Provenge Works Best for Patients With Low PSA, Scientists SayXconomy24/7 Wall St.all 19 news articles »
• Dendreon Declines as J&J Rival to Provenge Shows Benefits - Bloomberg 17 May, 2012, 8:03 am
  Live Trading NewsDendreon Declines as J&J Rival to Provenge Shows BenefitsBloomberg(DNDN), maker of the prostate cancer drug Provenge, dropped to its lowest value in four months after Johnson & Johnson (JNJ)'s rival medicine Zytiga helped high-risk patients in a study. Dendreon fell 11 percent to $7.65 at the close of trading in New ...Dendreon shares fall after disclosure of SEC probeCBS NewsDendreon Announces Presentation of PROVENGE Data at the 2012 American Society ...MarketWatch (press release)Dendreon: SEC Opens Probe, Possibly Tied To Provenge DisclosuresWall Street JournalDailyFinanceall 22 news articles »
• With UI treatment, dog defies odds of cancer - Champaign/Urbana News-Gazette 17 May, 2012, 6:18 am
  Champaign/Urbana News-GazetteWith UI treatment, dog defies odds of cancerChampaign/Urbana News-GazetteBear, a Shih-Tzu with terminal prostate cancer and a zest for life, keeps going after undergoing a rarely done surgery for dogs at the Universtity of Illinois College of Veterinary Medicine. URBANA — There are few things more grim for a dog than ...
• Advanced Prostate Cancer Drug May Help at Earlier Stage - U.S. News & World Report 17 May, 2012, 6:06 am
  New York TimesAdvanced Prostate Cancer Drug May Help at Earlier StageU.S. News & World ReportBy Amanda Gardner WEDNESDAY, May 16 (HealthDay News) -- A drug approved to treat advanced prostate cancer appears to help men who have localized high-risk prostate cancer if given before surgery. Adding Zytiga (abiraterone) to conventional hormonal ...Trial Supports Earlier Use of a Prostate Cancer DrugNew York TimesJ&J drug shows promise in high-risk prostate cancerReutersJ&J's Zytiga Helps Eliminate Early-Stage Prostate CancerBusinessWeekWall Street Journalall 116 news articles »